| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Denali Therapeutics Inc (NASDAQ: DNLI)
DNLI Technical Analysis
4
| As on 9th Jun 2023 DNLI STOCK Price closed @ 30.52 and we RECOMMEND Sell for LONG-TERM with Stoploss of 31.50 & Strong Sell for SHORT-TERM with Stoploss of 36.77 we also expect STOCK to react on Following IMPORTANT LEVELS. |
DNLISTOCK Price
| Open | 31.10 | Change | Price | % |
| High | 31.36 | 1 Day | -0.55 | -1.77 |
| Low | 30.50 | 1 Week | 0.30 | 0.99 |
| Close | 30.52 | 1 Month | 6.35 | 26.27 |
| Volume | 417783 | 1 Year | -15.40 | -33.54 |
| 52 Week High 47.45 | 52 Week Low 20.88 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| DNLI Daily Charts |
DNLI Intraday Charts |
Whats New @ Bazaartrend |
DNLI Free Analysis |
|
|
DNLI Important Levels Intraday
| RESISTANCE | 32.18 |
| RESISTANCE | 31.65 |
| RESISTANCE | 31.32 |
| RESISTANCE | 30.99 |
| SUPPORT | 30.05 |
| SUPPORT | 29.72 |
| SUPPORT | 29.39 |
| SUPPORT | 28.86 |
DNLI Forecast May 2024
| 4th UP Forecast | 57.4 |
| 3rd UP Forecast | 48.78 |
| 2nd UP Forecast | 43.45 |
| 1st UP Forecast | 38.12 |
| 1st DOWN Forecast | 22.92 |
| 2nd DOWN Forecast | 17.59 |
| 3rd DOWN Forecast | 12.26 |
| 4th DOWN Forecast | 3.64 |
DNLI Weekly Forecast
| 4th UP Forecast | 38.69 |
| 3rd UP Forecast | 36.07 |
| 2nd UP Forecast | 34.45 |
| 1st UP Forecast | 32.83 |
| 1st DOWN Forecast | 28.21 |
| 2nd DOWN Forecast | 26.59 |
| 3rd DOWN Forecast | 24.97 |
| 4th DOWN Forecast | 22.35 |
DNLI Forecast2024
| 4th UP Forecast | 84.9 |
| 3rd UP Forecast | 67.46 |
| 2nd UP Forecast | 56.68 |
| 1st UP Forecast | 45.9 |
| 1st DOWN Forecast | 15.14 |
| 2nd DOWN Forecast | 4.36 |
| 3rd DOWN Forecast | -6.42 |
| 4th DOWN Forecast | -23.86 |
Denali Therapeutics Inc ( NASDAQ USA Symbol : DNLI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
DNLI Business Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Address: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service